Navigation Links
Covaris Installed Instrument Base Reaches 500 Units

WOBURN, Mass., Nov. 26 /PRNewswire/ -- Covaris Incorporated today announced that during the summer of 2008, the company celebrated the shipment of its 500th instrument unit and continued another successful year throughout 2008. To accommodate this rapid business growth, Covaris is both strengthening its sales and marketing organization as well as implementing a 50% expansion of its main facility.

The Covaris business was built upon the proprietary and patented AFA(TM) (Adaptive Focused Acoustics) technology. The AFA technology has the ability of impart both thermal and non-contact control of application processes, which, in many cases, could not be obtained prior to the development of AFA technology. This unique and sustainable competitive advantage enables Covaris to develop a broad range of applications in Genomics, Proteomics and Drug Discovery research.

"There has been an increased systematic acceptance of our technology over the past few years. We are pleased to see our sample preparation tools gaining market acceptance and incorporated into daily research investigations throughout research institutions and pharmaceutical companies, such as the Broad Institute, GlaxoSmithKline and Merck," said Jim Laugharn, President and CEO of Covaris, "with the help of our customers, we have developed and optimized solutions for various key applications, such as DNA shearing for next-gen sequencing, RNA extraction for gene expression profiling, analyte and small molecule extraction from difficult tissue samples, compound formulation, and ADME/Tox."

"I'm truly impressed with the solid technology and product platform Covaris has developed and its experienced team of people with well-balanced knowledge ranging from acoustic physics, mechanical engineering to biophysics and molecular biology," commented Jennifer Wu, the newly hired Director of Marketing, "I'm honored and excited to join Covaris to further expedite marketing programs, market development and customer experience enhancement."

About Covaris, Inc.

Covaris, Inc. is a rapidly growing life science instrument company. Its proprietary instrument platform, based on patented Adaptive Focused Acoustic (AFA) technology brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid. Leading pharmaceutical and biotechnology companies worldwide are using Covaris instruments for RNA extraction, Compound Dissolution, Drug Metabolism tissue extraction, and much more. Information about Covaris is available at

SOURCE Covaris Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
2. Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility
3. Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc
4. Nanoscience Instruments, Inc. Introduces All-Diamond AFM Probes
5. Nikon Instruments Appoints LABSCO its Clinical Distributor in Six States
6. Instrumentation Laboratory Announces Passion & Results Awards Program
7. MKS Instruments Announces Third Quarter 2008 Earnings Conference Call
8. Advanced Instruments Acquires D & F Control Systems Inc.
9. World Leader in Bench Top Flow Chemistry Instruments ThalesNano, Inc. Introduces an Industry First Seminar Series
10. Nanoscience Instruments, Inc. Announces Distribution of Nascatec's Complete Line of Unique AFM Probes and Sensors
11. World Leader in Bench-Top Flow Chemistry Instruments ThalesNano, Inc. Closes Funding Round
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: ... been advised by its major shareholders, Clean Technology Fund ... United States based venture capital funds ... of Biorem (on a fully diluted, as converted basis), ... disposition of their entire equity holdings in Biorem to ...
(Date:6/27/2016)... Hill, N.C. (PRWEB) , ... June 27, 2016 ... ... U.S. commercial operations for Amgen, will join the faculty of the University ... serve as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):